ABSTRACT The gene encoding the human muscarinic receptor, type 1 (CHRM1), was genotyped from 245 samples of the Coriell Collection (Coriell Institute for Medical Research, Camden, NJ). Fifteen single nucleotide polymorphisms (SNPs) were discovered, 9 of which are located in the coding region of the receptor. Of these, 8 represent synonymous SNPs, indicating that CHRM1 is highly conserved in humans. Only a single allele was found to contain a nonsynonymous SNP, which encodes an amino acid change of Cys to Arg at position 417. This may have functional consequences because a C417S point mutation in rat M1 was previo usly shown to affect receptor binding and coupling. Furthermore, 0 of 4 SNPs within CHRM1 previously deduced from sequencing of the human genome were found in this study despite a prediction that a majority of such inferred SNPs are accurate. The consensus sequence of CHRM1 obtained in our study differs from the deposited reference sequence (AC NM_000738) in 2 adjacent nucleotides, leading to a V173M change, suggesting a sequencing error in the reference sequence. The extraordinary sequence conservation of the CHRM1 gene-coding region was unexpected as M1-knockout mice show only minimal functional impairments.
INTRODUCTION
The muscarinic receptor family, of which there are 5 subtypes (M1-M5), plays an important functional role throughout the body. Muscarinic receptors are involved in a variety of cell-type specific signaling pathways. These include the regulation of cyclic adenosine monophosphate concentration in the cell, activation of tyrosine and mitogen-activated kinases, and the regulation of ion channel function in the cell 1 .
The muscarinic receptors have a broad and overlapping distribution in the body. The M1, M2, and M4 receptors are the most abundant. The M1 receptor is found in the hippocampal and cortical regions of the brain as well as in the parasympathetic ganglia 2, 3, 4 . The M1 receptor is involved in many processes, including the initiation of seizures, learning and memory, and regulation of the force and rate of heart contractions 5, 6 . Because of its involvement in these processes, the M1 receptor is a compelling drug target for Alzheimer's disease and other neurological and psychiatric disorders 6 . Indeed, for the past 20 years, the cholinergic hypothesis has proposed that loss of cholinergic function is responsible for the cognitive symptoms of Alzheimer's 7 . It is thought that stimulation of the M1 receptor would alleviate some of the symptoms of Alzheimer's by several pathways, including increased secretion of the nontoxic a-amyloid peptide and decreased secretion of the toxic ß-amyloids generated from the amyloid precursor protein 8, 9 .
The M1 receptor is a member of the G-protein coupled receptor (GPCR) superfamily. Many GPCRs have been found to contain single nucleotide polymorphisms (SNPs) that are involved in disease susceptibility or drug response (for a review, see reference 10 ). The R16G allele in the ß 2 adrenergic receptor, for example, is associated with nocturnal asthma. Several of the serotonergic receptors have alleles associated with psychotic symptoms in Alzheimer's disease, whereas certain haplotypes of the µ opioid receptor have been associated with substance abuse 10 . Although the muscarinic receptors are thought to contribute to certain neurological and psychiatric disorders, no sequence variations or alleles have been found that affect susceptibility to these diseases or response to muscarinic agonists. In this study we have genotyped the CHRM1 gene-encoding human M1 receptor in 245 individuals of the Coriell Collection.
MATERIALS AND METHODS
Genotyping of CHRM1 was done as described in Wang et al 11 . Briefly, the genomic DNA from 245 individuals was amplified by polymerase chain reaction (PCR) (Applied Biosystems Gene Amp PCR System 9700, Foster City, CA) using the following primers: F1 5'GAGGAAGCCCTGTAGCG; R3 5'GATCACCACTTCGGAGCC; F2 5'AGCTCTGATGATCGGCCT; R1 5'CCAAGGAATACTTAATGTTAAGCCT. They were then sequenced on an Applied Biosystems 3700 DNA analyzer with a 3700 POP-6 polymer matrix. The resulting sequence tracings were then analyzed using Sequencher 4.0 (Gene Code Corp., Ann Arbor, MI). Haplotype analysis was done using an expectation-maximum algorithm 12 . Sequence alignments were done using the sequence alignment program Clustal W, which is freely available.
RESULTS AND DISCUSSION
The hM1 receptor gene (CHRM1 ) resides on chromosome 11. The CHRM1 gene consists of 1 large exon containing the entire coding region of the hM1 receptor. A promoter region and 3 noncoding exons for the hM1 gene based on similarity to the rat gene have been reported approximately 14 kilobases (kb) upstream of the hM1 coding region 13 . However, a Basic Local Alignment Search Tool (BLAST) search of these sequences against the human genome sequence showed these DNA segments to be 213 kb upstream of CHRM1 . The promoter region and noncoding exons were not sequenced in this study.
The human M1 muscarinic receptor gene, CHRM1 , was sequenced from 245 samples of the Coriell Collection. The samples used are ethnically diverse as follows: 100 Caucasians, 100 African Americans, 30 Asians, 10 Hispanics, and 7 Pacific Islanders. Fifteen SNPs were discovered, 9 of which are located in the coding region of the receptor (Table 1,   Table 1 Although the high conservation of the M1 gene in humans and mammals emphasizes its importance, the M1 gene is not essential for survival. A knockout of the M1 receptor in mice is not lethal; the M1-deficient mouse strain displays no significant differences in body weight, longevity, fertility, or overt behavior compared with wild-type mice 6 .
There is suggestive evidence that the 1 nonsynonymous variation, C417R, may exhibit a change in M1 receptor function. Cys 417, which is in transmembrane helix VII, is highly conserved; it is present in all 5 muscarinic subtypes in humans and all other species analyzed, including rhesus monkey, rat, mouse, chimpanzee, pig, and chicken. Cys 417 has been shown to influence receptorligand interactions. Previous mutagenesis studies with rat M1 have demonstrated that mutating Cys 417 to Ser resulted in increased receptor affinity to carbachol, a muscarinic agonist, and to several antagonists. The C417S mutation also caused a shift to the left in the carbachol dose response curve for phosphoinositol hydrolysis, resulting in an EC 50 value 13-fold lower than wild type 14 . Cys 417 therefore has a critical role in M1 receptor function. Because a Cys to Ser change is also more conservative than the Cys to Arg change encoded by a human allele, it is likely that this SNP will affect M1 receptor function and may warrant further study, despite its low frequency (1:490 alleles).
A haplotype analysis of CHRM1 SNPs was also done using an expectation-maximum algorithm. Haplotype analysis serves to characterize linkage disequilibrium in various populations 15, 16 and has the potential to identify disease-predisposing alleles in a population 12 . Only hM1 SNPs with a frequency greater than 1% were analyzed. Of the 15 SNPs found in the hM1 receptor, 6 fit this category, resulting in 8 distinct haplotypes (Table 2 ). Of these, by far the predominant one was wild type; 4 contained 1 SNP, and 3 involved 2 SNPs. This result could serve as a basis for studying possible disease association and may also involve SNPs adjacent to the CHRM1 gene.
The recent publication of the human genome sequence has brought to light many SNPs. There are 8 SNPs reported in the genomic sequence of CHRM1 (AC XM_006058). Of these, 4 SNPs were found as a result of the genome sequencing project and 4 SNPs were recently added to the accession sequence on the NCBI (National Center for Biotechnology Information) website. These were obtained from samples of 100 individuals, without frequency distribution provided, as a result of a separate genotyping of CHRM1 (unpublished). None of the 4 SNPs found as a result of sequencing for the human genome project were found in either study involving multiple samples, whereas all 4 of the SNPs identified in the alternate CHRM1 sequencing study were found. Failure to reproduce the 4 genomic SNPs is surprising because it has been previously reported that 85% of SNPs inferred from the human genome project are correct 17 . The consensus sequence obtained from this study also differed from the reference sequence for hM1 (AC NM_000738). The purpose of the NCBI reference sequences is to provide sequence standards for chromosomes, mRNA and proteins for use in mutation analysis, gene expression discovery, and polymorphism discovery and therefore should reflect the wild-type sequence of a particular gene. At base pairs 516 and 517, a GA in our consensus sequence was an AG in the reference sequence. This resulted in a Val to Met amino acid change at position 173. The V173M variation was not observed in this study, so it is either a very rare allele or (more likely) a sequencing error.
CONCLUSION
The results of genotyping the coding region of CHRM1 reveal that it is highly conserved in humans. Only 1 nonsynonymous SNP, C417R, was found in 1 heterozygote with potential consequences for receptor function. Even though the allele is rare, it may contribute to pathophysiology in some ethnic populations. The promoter region and other regulatory elements were not sequenced in this study. It is therefore possible that additional polymorphisms may be found in the regulatory elements of the CHRM1 gene. Polymorphisms in this region could influence receptor expression, thereby affecting drug response or disease susceptibility.
